[The importance of pharmacogenetic tests in evaluation of the effectiveness of methotrexate treatment in rheumatoid arthritis (part 2)].

Comments on this publication

ResearchGate members can add comments. Sign up now and post your comment!

Similar publications

• [The importance of pharmacogenetic tests in evaluation of the effectiveness of methotrexate treatment in rheumatoid arthritis (part 1)].

  Authors: Jerzy Swierkot, Ryszard Slęzak

  Postȩpy higieny i medycyny doświadczalnej (Online). 65:195-206.

• Are Thymidylate synthase and Methylene tetrahydrofolate reductase genes linked with methotrexate response (efficacy, toxicity) in Indian (Asian) rheumatoid arthritis patients?

  Authors: Yogita Ghodke, Arvind Chopra, Kalpana Joshi, Bhushan Patwardhan

  Clinical rheumatology. 27(6):787-9.

• Secondary failure to treatment with recombinant human IL-1 receptor antagonist in Chinese patients with rheumatoid arthritis.

  Authors: Jun Bao, Tao Yue, Wei Liu, Qing Zhang, Ling Zhou, Hu-Ji Xu, Sheng-Ming Dai

  Clinical rheumatology. 30(5):697-701.

• Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate.

  Authors: Yasuharu Nakashima, Masakazu Kondo, Hiroshi Harada, Takahiko Horiuchi, Takashi Ishinishi, Hiroshi Jojima, Koji Kuroda, Hisaaki Miyahara, Ryuji Nagamine, Hitoshi Nakashima, Takeshi Otsuka, Isao Saikawa, Eisuke Shono, Eiichi Suematsu, Tomomi Tsuru, Ken Wada, Yukihide Iwamoto

  Modern rheumatology / the Japan Rheumatism Association. 20(4):343-52.

• [Genetic polymorphisms in methylenetetrahydrofolate reductase and clinical response to chemotherapy in non-small cell lung cancer.]

  Authors: Meiqi Shi, Changming Gao, Jianzhong Wu, Jifeng Feng, Haixia Cao, Jianwei Lu, Lin Xu

  Zhongguo fei ai za zhi = Chinese journal of lung cancer. 9(6):519-524.

Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.